{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3"}]}],"title":"Week 24 Good (n = 1920)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9"}]}],"title":"Week 48 Good (n = 1753)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.1"}]}],"title":"Week 108 Good (n = 1525)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7"}]}],"title":"Week 156 Good (n = 1441)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8"}]}],"title":"Week 204 Good (n = 1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8"}]}],"title":"Week 264 Good (n = 1278)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1"}]}],"title":"Week 24 Moderate (n = 1920)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0"}]}],"title":"Week 48 Moderate (n = 1753)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.2"}]}],"title":"Week 108 Moderate (n = 1525)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7"}]}],"title":"Week 156 Moderate (n = 1441)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4"}]}],"title":"Week 204 Moderate (n = 1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1"}]}],"title":"Week 264 Moderate (n = 1278)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"A DAS-28 responder was defined as someone who met the European League Against Rheumatism \\[EULAR\\] criteria of a good or moderate response. A change of the DAS-28 score from Baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \\< -1.2 was a good response, \\< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \\> 3.2 to ≤ 5.1, a change from baseline of \\< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \\> 5.1, a change from baseline \\< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \\> 3.2.","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Percentage of Participants Who Were Disease Activity Score 28 (DAS-28) Responders at Weeks 24, 48, 108, 156, 204, and 264","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}